<div id="readability-page-1"><p>GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been assigned an average rating of &#34;Hold&#34; from the fifteen brokerages that are  covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have issued  a hold recommendation and five have issued  a buy recommendation on  the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $4.7292.</p><ul><li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li></ul><p>A number of equities analysts have recently weighed in on the stock. Bank of America  reissued a &#34;reduce&#34; rating on shares of GoodRx in a research report on Monday, January 5th. JPMorgan Chase &amp; Co. reduced their target price on GoodRx from $6.00 to $5.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, November 11th. Mizuho lowered their price target on GoodRx from $5.00 to $4.00 and set a &#34;neutral&#34; rating for the company in a report on Thursday, November 6th. Citigroup cut their price objective on GoodRx from $5.00 to $4.50 and set a &#34;buy&#34; rating on the stock in a report on Friday, January 9th. Finally, UBS Group lowered their target price on GoodRx from $4.25 to $4.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, November 6th.</p><p><b>Get Our Latest Stock Report on GoodRx</b></p><h2>Institutional Investors Weigh In On GoodRx</h2><ul><li>This healthcare stock making a buzz with 160% growth</li></ul><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. LSV Asset Management boosted its position in  GoodRx by 517.1% during the third quarter. LSV Asset Management now owns 2,354,581 shares of the company's stock valued at $9,960,000 after purchasing an additional 1,973,017 shares during the last quarter.  XTX Topco Ltd raised its stake in shares of  GoodRx by 281.2% during the 2nd quarter. XTX Topco Ltd now owns 272,273 shares of the company's stock worth $1,356,000 after purchasing an additional 200,852 shares in the last quarter.  Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of  GoodRx in the 3rd quarter valued at approximately $3,036,000.  Connor Clark &amp; Lunn Investment Management Ltd. grew its stake in shares of  GoodRx by 16.5% in the second quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 1,671,521 shares of the company's stock valued at $8,324,000 after buying an additional 236,896 shares in the last quarter.  Finally, Pacer Advisors Inc. acquired a new position in  GoodRx during the third quarter worth $3,687,000. 63.77% of the stock is currently owned by institutional investors and hedge funds. </p><h2>GoodRx Stock Performance</h2><p>Shares of NASDAQ:GDRX opened at $2.36 on Friday. The firm's 50 day simple moving average is $2.57 and its 200 day simple moving average is $3.33. GoodRx has a fifty-two week low of $2.10 and a fifty-two week high of $5.81. The company has a market capitalization of $801.05 million, a price-to-earnings ratio of 26.22, a P/E/G ratio of 0.90 and a beta of 1.50. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. </p><h2>GoodRx Company Profile</h2> (Get Free Report)<ul><li>Gene therapy: Why does it cost millions for a single treatment? </li></ul><p>GoodRx Holdings, Inc <span>NASDAQ: GDRX<span></span></span> operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.  </p><p>In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than GoodRx</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>My Epstein Story</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GoodRx Right Now?</h2><p>Before you consider GoodRx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p><p>While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GDRX

<p>GoodRx Holdings, Inc. (NASDAQ:GDRX) has received an average rating of "Hold" from 15 brokerages. Three analysts recommend selling, seven suggest holding, and five advise buying the stock. The average 12-month price target is $4.73. Recent adjustments include Bank of America's "reduce" rating and JPMorgan's target price cut from $6.00 to $5.00. GoodRx's stock opened at $2.36, with a 52-week range of $2.10 to $5.81. Institutional investors hold 63.77% of the stock, reflecting significant interest in the company.</p>

Market Beat

GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of "Hold" by Brokerages